X

Trial Profile

An Exploratory Study of αPD1-MSLN-CAR T Cells Secreting PD-1 Nanobodies for the Treatment of MSLN-positive Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 23 May 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BZDS 1901 (Primary) ; Cyclophosphamide; Fludarabine
Indications Cholangiocarcinoma; Colorectal cancer; Malignant-mesothelioma; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions
Sponsors Shanghai Cell Therapy Group

Most Recent Events

19 Apr 2023 Results (n=11; From July 20, 2020 to December 31, 2022) assessing the safety and efficacy of BZDS1901in treatment of malignant mesothelioma, presented at the 114th Annual Meeting of the American Association for Cancer Research.
10 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com